OncLive Global

Pamrevlumab May Address Unmet Need for Locally Advanced Pancreatic Cancer

February 17th 2021

February 17, 2021 – Pamrevlumab, a first-in-class inhibitor of connective tissue growth factor activity, is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) in a phase 3 trial for patients with unresectable locally advanced pancreatic cancer, a population in need of new options.

Fedratinib Approved in Europe for Newly Diagnosed and Previously Treated Myelofibrosis

February 9th 2021

February 9, 2021 - The European Commission has granted a full marketing authorization for fedratinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytopenia myelofibrosis who have not received JAK inhibitors or who have received ruxolitinib.

Teaching an Old Dog New Tricks: Repurposing Cancer Drugs to Combat COVID-19

February 5th 2021

February 4, 2021 - In response to the coronavirus disease 2019 pandemic, investigators have turned to tried-and-true cancer drugs to see whether they can be used to combat the virus.

Selinexor Approved in Israel for Multiple Myeloma, DLBCL

February 4th 2021

February 4, 2021 — The Israeli Ministry of Health has approved selinexor for the treatment of patients with multiple myeloma or diffuse large B-cell lymphoma.

Gilteritinib Receives Conditional Approval in China for FLT3+ AML

February 4th 2021

February 4, 2021 - The China National Medical Products Administration has granted a conditional approval to gilteritinib for use in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation detected by a validated test.

Ceralasertib/Durvalumab Combo Shows Efficacy in NSCLC Following Anti–PD-L1 Therapy

February 3rd 2021

February 3, 2021 - The combination of ceralasertib plus durvalumab improved overall response rate in patients with non‒small cell lung cancer who progressed on an anti-PD-1/PD-L1 therapy.

Larotrectinib Elicits Early Clinical Activity in NTRK Fusion–Positive Lung Cancer

February 2nd 2021

February 2, 2021 — Larotrectinib was found to elicit high response rates, durable responses, and to extend survival benefit in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.

QoL, Efficacy Data Support Use of Frontline Lorlatinib as New Standard in ALK+ NSCLC

February 2nd 2021

February 2, 2021 - The time to treatment deterioration for symptoms such as cough, dyspnea, and pain in the chest was found to be comparable between treatment-naïve patients with ALK-positive non–small cell lung cancer who received lorlatinib versus crizotinib.

cfDNA Methylation Assay Allows for Early Lung Cancer Detection

February 1st 2021

February 1, 2021 — Targeted circulating tumor DNA methylation marker panels possess the potential for early blood-based detection of lung cancer with a high sensitivity and specificity.

Pembrolizumab Approaches EU Approval for Expanded Indication in Relapsed/Refractory Hodgkin Lymphoma

February 1st 2021

February 1, 2020 - The European Medicines Agency’s Committee of Medicinal Products for Human Use has recommended a label expansion for pembrolizumab for use as a single agent in adult and pediatric patients aged 3 years and older with relapsed/refractory classical Hodgkin lymphoma for whom autologous stem cell transplant has failed or following at least 2 previous therapies when ASCT is not an option.